Health
Nature Communications reports promising effect of Idorsia’s lucerastat on kidney function in Fabry disease
In patients with impaired renal function or fast-deteriorating eGFR at baseline, lucerastat was associated with a marked attenuation of kidney function loss, suggesting a potential disease-modifying effectThe company is working with health authorities to find the optimal pathway to approval Allschwil, Switzerland – January 12, 2026Idorsia Ltd (SIX: IDIA) announces the publication of results from the pivotal Phase 3 MODIFY study and its open-label extension (OLE) evaluating lucerastat, an oral su
About this update from Idorsia Ltd.
[{"type":"image","alt":"Idorsia Pharmaceuticals Ltd","displaySize":"","headline":null,"caption":"Idorsia Pharmaceuticals Ltd","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":138,"url":"https://media.zenfs.com/en/globenewswire.com/78a4ac48860a5805262d0e653fb52e9a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/atcBYtwjtI326vFfueDYtQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/78a4ac48860a5805262d0e653fb52e9a","width":300,"height":138}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"In patients with impaired renal function or fast-deteriorating eGFR at baseline, lucerastat was associated with a marked attenuation of kidney function loss, suggesting a potential disease-modifying effect","length":205,"tagName":"p"}]},{"val":[{"type":"text","content":"The company is working with health authorities to find the optimal pathway to approval","length":86,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":291,"olType":false},{"type":"text","content":"Allschwil, Switzerland – January 12, 2026Idorsia Ltd (SIX: IDIA) announces the publication of results from the pivotal Phase 3 MODIFY study and its open-label extension (OLE) evaluating lucerastat, an oral substrate reduction therapy, in adults with Fabry disease. The data, published in Nature Communications, titled “Lucerastat, an oral therapy for Fabry disease: Results from a pivotal phase 3 study and its open-label extension”, reinforce lucerastat’s potential to address key unmet needs in Fabry disease, particularly in patients with renal impairment.","length":560,"tagName":"p"},{"type":"text","content":"About the MODIFY study (NCT03425539) and its open label extension (NCT03737214) MODIFY was a multicenter, double-blind, randomized, placebo-controlled, parallel-group study to determine the efficacy and safety of lucerastat as an oral monotherapy in adult patients with Fabry disease. 118 patients were randomized in a 2:1 ratio to either lucerastat or placebo. At the end of the double-blind period, 107 patients entered an open label extension study, to determine the long-term safety and tolerability of lucerastat oral therapy and to further evaluate its clinical efficacy on renal function, in adult patients with Fabry disease.","length":634,"tagName":"p"},{"type":"text","content":"The MODIF...